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Abstract 
Pulmonary arterial hypertension (PAH) is a debilitating dis-
ease characterized by constriction in the diameter of the pul-
monary arterial lumen.1·2 This leads to increased pressure 
and stress on the right ventricle of the heart, which may lead 
to heart failure and deathP Currently there are only a few 
treatment options for patients with PAH. Sildenafil, a phos-
phodiesterase type 5 (PDE-5) inhibitor, can be used to treat 
PAH. Sildenafil inhibits the degradation of cyclic guanosine 
monophosphate (cGMP). Increased cGMP concentration re-
'sults in pulmonary vasculature relaxation. Current clinical 
,trials have indicated that sildenafil can significantly improve 
.many of the symptoms of PAH. The trials have also shown 
·that when used appropriately, sildenafil can be used with 
minimal side effects. It is important for pharmacists and 
:other health care professionals to understand PAH as a dis-
:ease state and its treatment options, such as sildenafil. 
Introduction 
Pulmonary arterial hypertension (PAH) is a debilitating dis-
ease that, if left untreated, will lead to death.1 Pulmonary 
arterial hypertension is characterized by constriction in the 
diameter of the pulmonary arterial lumen.2 Since there is less 
space for blood to pass through, pressure begins to build up 
in the pulmonary artery. As a result, stress is exerted on the 
right side of the heart which can lead to heart failure and 
death. Due to its low prevalence, health care practitioners 
only have a few options for treating PAH: prostacyclins and 
prostacyclin analogues which cause dilation of blood vessels 
and a decrease in platelet adhesion, endothelin receptor an-
tagonists which prevent endothelin from constricting blood 
vessels or PDE-5 inhibitors which lead to vasodilation.2.3.4 
Other medications are typically used in conjunction with 
these options, such as diuretics, digoxin, calcium channel 
blockers and anticoagulants.4 
In their more widely advertised role, PDE-5 inhibitors are 
indicated to treat erectile dysfunction through their vasodila-
tion activity. Sildenafil, under the brand name of Viagra®, is a 
PDE-5 inhibitor currently indicated to treat erectile dysfunc-
tion.s Under the brand name Revatio®, sildenafil is indicated 
for PAH as well. It is important to note that in November 
2012, generic versions of sildenafil became available to the 
public. The intent of using sildenafil in PAH patients is to di-
late the pulmonary artery and ultimately relieve some of the 
stress on the heart.1 Current studies have indicated that sil-
denafil is an effective treatment for PAH. Through a review 
of current literature, the writers hope to review the presen-
tation and dangers of PAH and describe when sildenafil 
monotherapy is an appropriate treatment. 
Pulmonary Arterial Hypertension 
Pulmonary arterial hypertension is classified into three cate-
gories based on etiology: idiopathic, familial or associated. 
Both familial and idiopathic PAH can be present at birth or 
develop later in life. Associated PAH occurs when the disease 
is secondary to other pre-existing conditions such as autoim-
mune disease, congenital heart and lung disease, portal 
hypertension, the use of drugs similar in structure to 
amphetamines and Human Immunodeficiency Virus (HIV) 
infection among other conditions.I 
While the pathophysiology of PAH is not fully understood, its 
basic mechanisms have been identified. In patients with PAH, 
there is evidence of irregular expression of potassium chan-
nels in the endothelium and smooth muscle cells in the 
pulmonary artery. This irregular function can lead to an in-
hibited expression of the vasodilators nitric oxide and 
prostacyclin. Conversely, it can also lead to the overproduc-
tion of vasoconstrictors, thromboxane A2 and endothelin-1. 
These changes result in increased vasoconstriction, inflam-
mation and thrombosis. In PAH patients, high cellular prolif-
eration is present in the vascular wall of the pulmonary ar-
tery.2,3 This leads to increased pressure and stress on the 
right ventricle of the heart; stress which, in time, can lead to 
heart failure and death. 
Family history is an effective tool in identifying patients who 
have a higher risk of acquiring PAH.1 While no age, ethnic or 
racial group is categorized as high risk, PAH does on average 
affect more women than men. Additionally, PAH is more 
prevalent in patients with associated conditions such as 
autoimmune disease, congenital heart and lung disease, por-
tal hypertension, HIV infection and the use of some drugs 
such as fenfluramine, cocaine or amphetamines. Patients 
with PAH may present with side effects similar to other heart 
and lung conditions such as chest pain, dizziness, fainting, 
fatigue, swelling, and shortness of breath and light-
headedness while exercising. Since signs and symptoms are 
not specific to PAH, the disease may be advanced at time of 
diagnosis.4 Perfusion lung scan, echocardiogram, right heart 
catheterization, electrocardiogram and chest x-rays are all 
indicative in the diagnosis of PAH. 
Sildenafil and General Prescribing Information 
Sildenafil inhibits PDE-5 in smooth muscle of pulmonary 
vasculature where PDE-5 is responsible for the degradation 
of cyclic guanosine monophosphate (cGMP). Increased cGMP 
concentration results in pulmonary vasculature relaxation. 
This occurs when PDE-5 breaks down cGMP that forms in 
response to increased nitric oxide. Increased intracellular 
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cGMP inhibits calcium entry into the cell, which results in 
smooth muscle relaxation. Sildenafil is available as both an 
intravenous injection (IV) and an oral medication. If adminis-
tering as an IV, the dose of sildenafil is 10 mg IV bolus three 
times per day; if taking the oral formulation, the dose is 20 
mg by mouth three times per day (four to six hours apart) 
without regard to meals. The onset of action is about 60 min-
utes, and its duration of action is two to four hours. Sudden 
cessation of sildenafil could result in an exacerbation of PAH. 
There is no dose adjustment needed in renal impairment or 
in hepatic impairment with Child-Pugh class A or B. This 
drug is a major substrate of CYP3A4 and a minor substrate of 
CYP1A2, CYP2C19, CYP2D6, and CYP2El. It is also a weak 
inhibitor of CYP2C9 and CYP3A4. Therefore, dose adjust-
ments are required when using potent CYP3A4 inhibitors, 
except with erythromycin. Concomitant use of sildenafil and 
itraconazole/ketoconazole is not recommended; concurrent 
use with protease inhibitors and organic nitrates is contrain-
dicated. Sildenafil should be used with caution in patients 
over 65 years of age, and this drug is Pregnancy Category B. 
Chronic use in children is not recommended. Patients should 
avoid drinking grapefruit juice while taking this drug.s 
Additionally, blood pressure and heart rate should be moni-
tored as hypotension may develop while taking sildenafil. 
Patients at increased risk of hypotension are those taking an 
antihypertensive medication or those with aortic stenosis, 
hypertrophic obstructive cardiomyopathy or fluid depletion. 
If the patient develops pulmonary edema when taking this 
drug, sildenafil should be discontinued as this could be pul-
monary veno-occlusive disease. Sildenafil should be used 
with caution in people taking alpha-blockers, bosentan, ni-
trates and other erectile dysfunction drugs. Adverse effects 
such as flushing, diarrhea, myalgia and visual disturbances 
may be increased with adult doses >100 mg/24 hours. Over 
10 percent of patients experience a headache and dyspepsia. 
Other common adverse effects are erythema, dizziness, in-
somnia, increased liver function tests (LFTs), urinary tract 
infection and dyspnea.s 
Selected Clinical Trials 
Impact of First-line Sildenafil Monotreatment for Pulmonary 
Arterial Hypertension, a study conducted by the Keio and 
Kyorin University Hospitals, analyzed the efficacy of silde-
nafil as a monotreatment for PAH. Fifty-seven patients with 
New York Heart Association functional class (NYHA FC) rat-
ings of I, II, or III were enrolled; four patients dropped out of 
the study due to high cost of off-label use, and seven patients 
with Eisenmenger Syndrome were dismissed because of 
their differing clinical characteristics from other patients 
with PAH. The remaining patients were given 20 mg silde-
nafil three times daily as a monotreatment from January 
2003 to December 2010. A 6-minute walk distance (6MWD; 
an independent predictor of death in patients with PAH) and 
B-type natriuretic peptide (BNP) levels were evaluated be-
fore treatment began and again during follow-up.6 
It was found that the BNP tended to be lower after sildenafil 
treatment, but the results were not significant. Hemody-
namic parameters, however, such as the pulmonary vascular 
resistance (14.6±8.7 versus 11.6± 8.6 Wood units, P<0.05), 
mean pulmonary arterial pressure (PAP: 52.1±14.0 versus 
45.7±15.7 mmHg, P<0.01), mean right atrial pressure (RA: 
8.0±5.5 versus 6.4±4.4 mmHg, P<0.05), and cardiac output 
(CO: 3.7±1.6 versus 4.2±1.9 L/min, P<0.05), improved signifi-
cantly following sildenafil treatment in the enrolled patients 
as a whole. These results are indicative of sildenafil's positive 
cardiovascular effects, which result in improved cardiac 
function . NYHA FC either improved (n=12, 26.1 percent) or 
was maintained (n=30, 65.2 percent) in 42 of 46 patients; 
NYHA FC worsened in four patients (8.7 percent). Due to the 
NYHA FC maintenance or improvement rate of 91.3 percent, 
the study concluded that sildenafil demonstrated superior 
efficacy as a monotreatment for PAH. Critiques of this study 
included its lack of control group and small study popula-
tion.6 
Clinical Efficacy of Sildenafil in Primary Pulmonary Hyper-
tension, a randomized, double-blind crossover study, com-
pared the efficacy of sildenafil with placebo in patients with 
primary pulmonary hypertension. Change in exercise time on 
a treadmill was used as a primary endpoint. Patients were 
randomized into a placebo group or sildenafil group with 
doses ranging from 25 to 100 mg three times daily based on 
body weight. A baseline evaluation was done before treat-
ment began, and again after six weeks of treatment. After the 
six-week evaluation, patients were crossed over to the ther-
apy alternative to their current treatment (i.e. the sildenafil 
group ceased sildenafil treatment and began the placebo 
regimen, and vice versa). A final evaluation was performed 
after another six weeks of treatment.7 
Twenty-two patients completed the study. Exercise time 
increased by 44 percent from 475 ± 168 seconds at the end 
of placebo phase to 686 ± 224 seconds at the end of sildenafil 
phase (p < 0.0001). It was also noted that cardiac index im-
proved from 2.80 ± 0.9 l/m2 to 3.45 ± 1.11/mZ (p < 0.0001). 
Pulmonary artery systolic pressure decreased from 105.23 ± 
17.82 mm Hg to 98.50 ± 24.38 mmHg, but these results were 
found to be insignificant. Patients also reported significant 
improvements in dyspnea and fatigue in a Quality of Life 
questionnaire. From these results it was concluded that sil-
denafil significantly improves exercise tolerance, cardiac in-
dex, and quality of life in patients with primary pulmonary 
hypertension. No serious side effects were noted. While 
these results reflect those of other studies, the authors ac-
knowledged that a larger study population, longer treatment 
duration, and a washout period between crossover treat-
ment would help lend credibility to these findings.7 
Sildenafil Citrate Therapy for Pulmonary Arterial Hyperten-
sion, a double-blind, placebo-controlled study conducted by 
the Sildenafil Use in Pulmonary Arterial Hypertension 
(SUPER) Study Group, used the 6MWD test indicating a 
change in exercise capacity as a primary end point of silde-
nafil efficacy. Placebo or sildenafil treatment (20, 40, or 80 
mg) orally three times daily for 12 weeks was randomly as-
signed to 278 patients with PAH class II or III. Among the 
265 patients who completed the study, an increase in the 
6MWD was observed in all groups receiving sildenafil in 
comparison to the placebo. Improvement was noted at week 
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four and maintained at weeks eight and twelve. The ob-
served treatment-related increases of 45 to 50 meters is 
similar to the increases observed with other PAH medica-
tions such as intravenous epoprostenol (47 m), inhaled ilo-
prost (36 m), and oral bosentan (44 m), and is higher than 
the increase seen with the use of subcutaneous trepostinil 
(16 m). There was no evidence of a dose-response relation-
ship associated with exercise capacity. It is possible that this 
is due to complete 5-PDE inhibition at the lowest dose.s 
Patients receiving sildenafil treatment also experienced im-
provements in functional class. After twelve weeks of treat-
ment, seven percent of patients receiving placebo noted an 
improvement of at least one functional class. The propor-
tions of FC improvements for those receiving treatment were 
28 percent for those receiving 20 mg of sildenafil (P=0.003), 
36 percent for those receiving 40 mg (P<0.001), and 42 per-
cent for those receiving 80 mg (P<0.001). A significant de-
crease from baseline in mean pulmonary-artery pressure 
and pulmonary vascular resistance was also noted in those 
taking sildenafil from the placebo group. The proportion of 
hospitalizations for worsening PAH was greater in the pla-
cebo group than in the combined sildenafil treatment groups 
(P=0.02).8 
Adverse events experienced (such as headache, dyspepsia 
and back pain) were mild to moderate in intensity for all 
treatment groups.a 
Two hundred seventy-seven patients were enrolled in a 12-
week, double-blind, randomized, placebo-controlled trial 
(SUPER-1), a continuation of the original SUPER study. Two 
hundred fifty-nine patients completed the study and entered 
into an open-label, uncontrolled extension study (SUPER-2) 
that continued until the last patient had completed three 
years of sildenafil treatment. The median duration of silde-
nafil treatment was 1,242 days. Patients were titrated to a 
dose of 80 mg of sildenafil three times daily for treatment of 
PAH. As in previous studies, the 6MWD test was used as a 
primary endpoint. At three years post-baseline, 127 patients 
(49 percent) had an increased 6MWD. Sixty-four percent of 
patients either improved or maintained their functional 
class; 81 patients noted improvement, while 86 patients 
maintained their current level of functioning. Treatment with 
sildenafil was generally well-tolerated, and noted adverse 
events were of mild to moderate severity. The study authors 
acknowledged that an increased treatment duration would 
be necessary to support these findings of efficacy. 9 
While more thorough and lengthy studies would further vali-
date recent findings, all current evidence suggests that silde-
nafil is an effective treatment for PAH. It has been shown to 
significantly improve pulmonary vascular resistance, mean 
pulmonary arterial pressure, mean right atrial pressure, car-
diac output, exercise capacity, FC and quality of life. Sildenafil 
was found to be generally well-tolerated among all patients 
studied, with mild to moderate side effects: 
Because most studies were aimed at assessing sildenafil's 
efficacy as a monotherapy compared to placebo, more stud-
ies regarding specific dosing effectiveness would be helpful 
in determining the optimal dosage for PAH treatment. Given 
current findings, however, the recommended daily dose for 
PAH treatment remains at 20 mg three times daily.s There is 
no evidence suggesting that sildenafil treatment has a de-
creased efficacy or increased adverse effects in comparison 
to other PAH therapies. 
Pharmaceutical Application 
It is important for health care professionals, especially 
pharmacists, to be knowledgeable about sildenafil and PAH. 
Because sildenafil has many drug interactions and possible 
adverse events associated with its use, pharmacists can play 
a vital role in therapy by counseling patients when they 
receive this medication. Although PAH is not a common con-
dition, pharmacists need to be aware of PAH and to know the 
signs and symptoms of PAH as well as how to treat it in order 
to improve the patient's quality of life. Sildenafil can signifi-
cantly improve the quality of life of a patient with PAH and 
should be considered as an option for treatment in a PAH 
patient. Specifically, sildenafil is one of two treatment op-
tions indicated for functional class II patients with PAH, and 
one of five treatment options indicated for functional class III 
patients.10 
Conclusion 
Pulmonary arterial hypertension is the constriction of the 
pulmonary arterial lumen that can result in stress on the 
right side of the heart which ultimately leads to heart failure 
and death. There are only a few treatment options for PAH, 
and sildenafil, a PDE-5 inhibitor, is one of the options due to 
its ability to dilate the pulmonary artery. Through various 
studies, sildenafil has been proven to be effective in treating 
PAH as monotherapy with mild to moderate adverse events 
while improving dyspnea, fatigue and quality of life. It is im-
portant for pharmacists and other health care professionals 
to understand P AH as a disease state and to counsel patients 
on appropriate treatment options, including sildenafil. 
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